11 3 EA7361 "Structure, dynamic, function and expression of broad spectrum β-lactamases", ABSTRACT 31 Polymyxin antibiotics are a last-line treatment for multidrug-resistant Gram-negative 32 bacteria. However, the emergence of colistin resistance, including the spread of mobile mcr 33 genes, necessitates the development of improved diagnostics for the detection of colistin-34 resistant organisms in hospital settings. The recently developed MALDIxin test enables 35 detection of colistin resistance by MALDI-TOF mass spectrometry in less than 15 minutes 36 but is not optimized for the mass spectrometers commonly found in clinical microbiology 37 laboratories. In this study, we adapted the MALDIxin test for the MALDI Biotyper Sirius 38 MALDI-TOF mass spectrometry system (Bruker Daltonics). We optimized the sample 39 preparation protocol using a set of 6 MCR-expressing Escherichia coli clones and validated the 40 assay with a collection of 40 E. coli clinical isolates, including 19 MCR producers, 12 41 chromosomally-resistant isolates and 9 polymyxin-susceptible isolates. We calculated 42 Polymyxin resistance ratio (PRR) values from the acquired spectra; a PRR value of zero, 43 indicating polymyxin susceptibility, was obtained for all colistin-susceptible E. coli isolates, 44 whereas positive PRR values, indicating resistance to polymyxins, were obtained for all 45 resistant strains independent of the genetic basis of resistance. Thus, we report a preliminary 46 feasibility study showing that an optimized version of the MALDIxin test, adapted for the 47 routine MALDI Biotyper Sirius, provides an unbiased, fast, reliable, cost-effective and high-48 throughput way of detecting colistin resistance in clinical E. coli isolates.
INTRODUCTION 50
Antibiotic resistance is an issue of global importance and one of the defining public health 51 concerns of our time (1). The limited pipeline of novel antimicrobials and the spread of 52 multidrug-resistant (MDR) organisms have increased our reliance on a few last-line 53 antibiotics for the treatment of MDR Gram-negative bacteria. Chief amongst these last-resort 54 agents are the polymyxin antibiotics, polymyxin B and colistin (2, 3) . colistin resistance (MCR) enzymes (6). The first MCR enzyme, MCR-1, was reported in 63 2016 (7) and this discovery was followed by the rapid identification of other mobile 64 polymyxin resistance genes. To date a further eight MCR proteins have been described. 65 These enzymes cluster into four main groups: MCR-1-like (MCR-1, -2, -6), MCR-3-like 66 (MCR-3, -7, -8, -9), MCR-4-like (MCR-4) and MCR-5-like (MCR-5) (8) (9) (10) (11) .
68
Detection of colistin resistance currently relies on minimum inhibitory concentration (MIC) 69 determination using broth microdilution (BMD), a slow process which, despite being the gold 70 standard for polymyxin susceptibility testing, has been subject to reliability and 71 standardization problems (6, 12) . Additionally, routine detection of colistin resistance by 72 conventional methods such as polymerase-chain-reaction (PCR)-based testing is challenging 73 due to the wide range of chromosomal mutations which can give rise to colistin resistance (6) 74 and the low sequence identity of the mcr genes (using mcr-1 as a reference: mcr-2, 77.6%; 75 mcr-3, 49.2%; mcr-4, 46.8%; mcr-5, 50. 5%; mcr-6, 78.3%; mcr-7, 49.9%; mcr-8, 47.8%; 76 mcr-9, 57.69%). This means that PCR-based detection methods are insensitive to all but the 77 best-characterized chromosomal mutations and to the emergence of new mcr genes.
78
Therefore, there is an urgent need to develop a fast, robust and high-throughput assay, 79 accessible to all diagnostic microbiology laboratories, that uses an unbiased approach to 80 detect colistin resistance arising from both known and novel chromosomal mutations or MCR 81 proteins.
83
Recently we developed the MALDIxin test, a diagnostic tool based on Matrix-assisted laser 84 desorption/ionization-time of flight (MALDI-TOF) mass spectrometry that can be used to 85 detect colistin resistance using intact bacteria in less than 15 minutes (13, 14 (Table 1) , as necessary. Identification of mcr genes was 109 performed by multiplex PCR as previously described (15) and β-lactamases genes were 110 identified using in-house multiplex PCR protocols. The colistin MIC of all tested strains was determined three times and was found to be identical 120 at each repeat. Results were interpreted using EUCAST breakpoints as updated in 2018 121 (http://www.eucast.org/clinical_breakpoints/). indicates colistin resistance. PRR 1919 values were determined by dividing the intensity of the 144 peak at m/z 1919 alone by the native Lipid A peak and PRR 1927 values were determined by 145 dividing the intensity of the peak at m/z 1927 alone by the native Lipid A peak. All mass 146 spectra were generated and analyzed in technical triplicate (i.e. measurements of each sample 147 were repeated three times) and biological triplicate (i.e. the entire experiment was repeated on 148 three separate days using separately grown bacteria and separate materials). were not found to carry an mcr gene by multiplex PCR (15), and are thus likely to harbor 176 chromosomal mutations that lead to colistin resistance, we were able to detect a peak at m/z 177 1927.2, in addition to the native Lipid A peak. This signal corresponds to the addition of L-
178
Ara4N to the 4ˊ-phosphate of Lipid A, resulting in an increase of +131 m/z compared to the 179 native Lipid A peak (Figure 1, middle row) . In several of these isolates, peaks at both m/z 180 1919.2 and m/z 1927.2 were observed, suggesting that these organisms possess Lipid A 181 species modified with both pETN and L-Ara4N (Table 1) . Finally, for colistin susceptible E. 182 coli clinical isolates, a single peak at m/z 1796.2 was detected, confirming that the Lipid A in 183 these strains is unmodified. Using these spectra, PRR values for all strains were calculated. (Table 1) . 190 191 The work presented here broadens the applicability of our previously developed MALDIxin 192 test (13) and represents an unbiased, fast, robust, cost-effective and high-throughput method For this analysis we used the recently released MALDI Biotyper Sirius mass spectrometer.
189

DISCUSSION
203
This system differs from previous Biotyper systems as it can operate in both positive and 204 negative ion modes. Analytes that are acidic in nature, such as those containing phosphate or 205 carboxylate groups, are more efficiently ionized by the generation of anions (16). As such, 206 detection of Lipid A, which contains both long chain fatty acid and phosphate groups (at 207 carbon 1 and 4ˊ), is superior when anions are generated using the negative ion mode.
208
Therefore, the newly introduced negative ion mode of the MALDI Biotyper Sirius allows 209 efficient detection of both native Lipid A and its modified forms. Nonetheless, although the 210 MALDI Biotyper Sirius is the optimal mass spectrometer for the assay as described here,
211
Lipid A can also be detected using any MALDI-TOF mass spectrometer supporting negative- The diagnostic assay described in this study will initially be made available to users of the 240 MALDI Biotyper Sirius, along with full application support, for research use only (RUO) 241 validation studies. This will be followed by the transformation of an already existing, RUO, Overall, this study represents a major step towards for the routine application of MALDI-252 TOF-based detection of colistin resistance and lays the foundations for a rapid diagnostic test 253 for colistin resistance that will be readily accessible to most clinical microbiology Colistin susceptible strains J53 0.5 --0.00±0.00 0.00±0.00 0.00±0.00 1608071881 0.25 --0.00±0.00 0.00±0.00 0.00±0.00 1608075385 0.12 -penicillinase 0.00±0.00 0.00±0.00 0.00±0.00 1608078105 0.25 -penicillinase 0.00±0.00 0.00±0.00 0.00±0.00 2H6 0.25 -CTX-M-15 0.00±0.00 0.00±0.00 0.00±0.00 2 E10 0.25 -CTX-M-14 0.00±0.00 0.00±0.00 0.00±0.00 1A6 0.25 -NDM-4, CTX-M-15, OXA-1 0.00±0.00 0.00±0.00 0.00±0.00 1C2 0.5 -VIM-1 0.00±0.00 0.00±0.00 0.00±0.00 2A1 0.25 -OXA-48, CTX-M-15 0.00±0.00 0.00±0.00 0.00±0.00
